Starling Oncology Inc. Wt (NASDAQ: STLNW) Stock Competitors & Peer Comparison

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, HCA has a market cap of 92.9B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while HCA trades at $429.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas HCA's P/E ratio is 14.82. In terms of profitability, STLNW's ROE is N/A, compared to HCA's ROE of -1.13%. Regarding short-term risk, STLNW is less volatile compared to HCA. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check HCA's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, THC has a market cap of 22.6B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while THC trades at $280.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas THC's P/E ratio is 16.29. In terms of profitability, STLNW's ROE is N/A, compared to THC's ROE of +0.51%. Regarding short-term risk, STLNW is less volatile compared to THC. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check THC's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, FMS has a market cap of 12.6B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while FMS trades at $23.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas FMS's P/E ratio is 8.80. In terms of profitability, STLNW's ROE is N/A, compared to FMS's ROE of +0.07%. Regarding short-term risk, STLNW is less volatile compared to FMS. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check FMS's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, EHC has a market cap of 11.9B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while EHC trades at $120.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas EHC's P/E ratio is 20.59. In terms of profitability, STLNW's ROE is N/A, compared to EHC's ROE of +0.25%. Regarding short-term risk, STLNW is less volatile compared to EHC. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check EHC's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, DVA has a market cap of 11.2B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while DVA trades at $173.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas DVA's P/E ratio is 13.58. In terms of profitability, STLNW's ROE is N/A, compared to DVA's ROE of -1.24%. Regarding short-term risk, STLNW is less volatile compared to DVA. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check DVA's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, UHS has a market cap of 10.7B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while UHS trades at $177.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas UHS's P/E ratio is 7.87. In terms of profitability, STLNW's ROE is N/A, compared to UHS's ROE of +0.21%. Regarding short-term risk, STLNW is less volatile compared to UHS. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check UHS's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, ENSG has a market cap of 10.5B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while ENSG trades at $179.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas ENSG's P/E ratio is 26.01. In terms of profitability, STLNW's ROE is N/A, compared to ENSG's ROE of +0.17%. Regarding short-term risk, STLNW is less volatile compared to ENSG. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check ENSG's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while OSH trades at $39.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas OSH's P/E ratio is -17.65. In terms of profitability, STLNW's ROE is N/A, compared to OSH's ROE of +4.64%. Regarding short-term risk, STLNW is more volatile compared to OSH. This indicates higher risk in terms of short-term price fluctuations for STLNW.Check OSH's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, HIMS has a market cap of 7.5B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while HIMS trades at $33.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas HIMS's P/E ratio is -52.80. In terms of profitability, STLNW's ROE is N/A, compared to HIMS's ROE of -0.30%. Regarding short-term risk, STLNW is less volatile compared to HIMS. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check HIMS's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, PACS has a market cap of 7B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while PACS trades at $44.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas PACS's P/E ratio is 23.42. In terms of profitability, STLNW's ROE is N/A, compared to PACS's ROE of +0.27%. Regarding short-term risk, STLNW is less volatile compared to PACS. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check PACS's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, CHE has a market cap of 7B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while CHE trades at $540.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas CHE's P/E ratio is 24.74. In terms of profitability, STLNW's ROE is N/A, compared to CHE's ROE of +0.29%. Regarding short-term risk, STLNW is less volatile compared to CHE. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check CHE's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while LHCG trades at $169.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas LHCG's P/E ratio is 82.83. In terms of profitability, STLNW's ROE is N/A, compared to LHCG's ROE of +0.04%. Regarding short-term risk, STLNW is less volatile compared to LHCG. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check LHCG's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, LFST has a market cap of 4.8B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while LFST trades at $12.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas LFST's P/E ratio is 93.92. In terms of profitability, STLNW's ROE is N/A, compared to LFST's ROE of +0.03%. Regarding short-term risk, STLNW is less volatile compared to LFST. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check LFST's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, CON has a market cap of 4.5B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while CON trades at $35.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas CON's P/E ratio is 24.18. In terms of profitability, STLNW's ROE is N/A, compared to CON's ROE of +0.47%. Regarding short-term risk, STLNW is less volatile compared to CON. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check CON's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, NHC has a market cap of 3.6B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while NHC trades at $233.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas NHC's P/E ratio is 29.65. In terms of profitability, STLNW's ROE is N/A, compared to NHC's ROE of +0.13%. Regarding short-term risk, STLNW is less volatile compared to NHC. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check NHC's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, OPCH has a market cap of 3.5B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while OPCH trades at $23.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas OPCH's P/E ratio is 13.78. In terms of profitability, STLNW's ROE is N/A, compared to OPCH's ROE of +0.16%. Regarding short-term risk, STLNW is less volatile compared to OPCH. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check OPCH's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while AMED trades at $100.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas AMED's P/E ratio is 39.30. In terms of profitability, STLNW's ROE is N/A, compared to AMED's ROE of +0.11%. Regarding short-term risk, STLNW is more volatile compared to AMED. This indicates higher risk in terms of short-term price fluctuations for STLNW.Check AMED's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, AVAH has a market cap of 2.9B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while AVAH trades at $13.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas AVAH's P/E ratio is 19.35. In terms of profitability, STLNW's ROE is N/A, compared to AVAH's ROE of +1.50%. Regarding short-term risk, STLNW is less volatile compared to AVAH. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check AVAH's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, BKD has a market cap of 2.8B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while BKD trades at $11.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas BKD's P/E ratio is -20.34. In terms of profitability, STLNW's ROE is N/A, compared to BKD's ROE of +4.06%. Regarding short-term risk, STLNW is less volatile compared to BKD. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check BKD's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, ACHC has a market cap of 2.6B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while ACHC trades at $27.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas ACHC's P/E ratio is 13.98. In terms of profitability, STLNW's ROE is N/A, compared to ACHC's ROE of -0.50%. Regarding short-term risk, STLNW is less volatile compared to ACHC. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check ACHC's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, GRDN has a market cap of 2.4B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while GRDN trades at $37.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas GRDN's P/E ratio is 33.25. In terms of profitability, STLNW's ROE is N/A, compared to GRDN's ROE of +0.31%. Regarding short-term risk, STLNW is less volatile compared to GRDN. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check GRDN's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, ADUS has a market cap of 2.3B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while ADUS trades at $120.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas ADUS's P/E ratio is 18.09. In terms of profitability, STLNW's ROE is N/A, compared to ADUS's ROE of +0.10%. Regarding short-term risk, STLNW is less volatile compared to ADUS. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check ADUS's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, MD has a market cap of 2.2B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while MD trades at $26.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas MD's P/E ratio is 11.87. In terms of profitability, STLNW's ROE is N/A, compared to MD's ROE of +0.20%. Regarding short-term risk, STLNW is less volatile compared to MD. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check MD's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, SEM has a market cap of 2B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while SEM trades at $16.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas SEM's P/E ratio is 15.43. In terms of profitability, STLNW's ROE is N/A, compared to SEM's ROE of +0.08%. Regarding short-term risk, STLNW is less volatile compared to SEM. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check SEM's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, ASTH has a market cap of 2B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while ASTH trades at $39.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas ASTH's P/E ratio is 37.84. In terms of profitability, STLNW's ROE is N/A, compared to ASTH's ROE of +0.05%. Regarding short-term risk, STLNW is less volatile compared to ASTH. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check ASTH's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, SGRY has a market cap of 1.9B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while SGRY trades at $14.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas SGRY's P/E ratio is 37.23. In terms of profitability, STLNW's ROE is N/A, compared to SGRY's ROE of -0.05%. Regarding short-term risk, STLNW is less volatile compared to SGRY. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check SGRY's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, SNDA has a market cap of 1.9B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while SNDA trades at $39.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas SNDA's P/E ratio is -6.39. In terms of profitability, STLNW's ROE is N/A, compared to SNDA's ROE of -0.26%. Regarding short-term risk, STLNW is less volatile compared to SNDA. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check SNDA's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while AMEH trades at $40.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas AMEH's P/E ratio is 39.25. In terms of profitability, STLNW's ROE is N/A, compared to AMEH's ROE of +0.05%. Regarding short-term risk, STLNW is less volatile compared to AMEH. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check AMEH's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, AGL has a market cap of 1.6B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while AGL trades at $96.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas AGL's P/E ratio is -6.27. In terms of profitability, STLNW's ROE is N/A, compared to AGL's ROE of -1.19%. Regarding short-term risk, STLNW is less volatile compared to AGL. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check AGL's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, ARDT has a market cap of 1.6B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while ARDT trades at $10.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas ARDT's P/E ratio is 8.85. In terms of profitability, STLNW's ROE is N/A, compared to ARDT's ROE of +0.05%. Regarding short-term risk, STLNW is less volatile compared to ARDT. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check ARDT's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, HCSG has a market cap of 1.6B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while HCSG trades at $22.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas HCSG's P/E ratio is 18.22. In terms of profitability, STLNW's ROE is N/A, compared to HCSG's ROE of +0.24%. Regarding short-term risk, STLNW is less volatile compared to HCSG. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check HCSG's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, INNV has a market cap of 1.5B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while INNV trades at $10.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas INNV's P/E ratio is -121.78. In terms of profitability, STLNW's ROE is N/A, compared to INNV's ROE of -0.09%. Regarding short-term risk, STLNW is less volatile compared to INNV. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check INNV's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, PNTG has a market cap of 1.4B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while PNTG trades at $38.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas PNTG's P/E ratio is 29.45. In terms of profitability, STLNW's ROE is N/A, compared to PNTG's ROE of +0.10%. Regarding short-term risk, STLNW is less volatile compared to PNTG. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check PNTG's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, AMN has a market cap of 1.3B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while AMN trades at $34.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas AMN's P/E ratio is 11.45. In terms of profitability, STLNW's ROE is N/A, compared to AMN's ROE of +0.15%. Regarding short-term risk, STLNW is less volatile compared to AMN. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check AMN's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, NUTX has a market cap of 1.3B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while NUTX trades at $185.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas NUTX's P/E ratio is 7.35. In terms of profitability, STLNW's ROE is N/A, compared to NUTX's ROE of +0.52%. Regarding short-term risk, STLNW is less volatile compared to NUTX. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check NUTX's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while BKDT trades at $77.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas BKDT's P/E ratio is N/A. In terms of profitability, STLNW's ROE is N/A, compared to BKDT's ROE of +4.06%. Regarding short-term risk, STLNW is more volatile compared to BKDT. This indicates higher risk in terms of short-term price fluctuations for STLNW.Check BKDT's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, USPH has a market cap of 1.2B. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while USPH trades at $78.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas USPH's P/E ratio is 30.77. In terms of profitability, STLNW's ROE is N/A, compared to USPH's ROE of -0.01%. Regarding short-term risk, STLNW is less volatile compared to USPH. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check USPH's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, TALK has a market cap of 879.4M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while TALK trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas TALK's P/E ratio is 774.34. In terms of profitability, STLNW's ROE is N/A, compared to TALK's ROE of +0.00%. Regarding short-term risk, STLNW is less volatile compared to TALK. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check TALK's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, GMRS has a market cap of 728.1M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while GMRS trades at $13.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas GMRS's P/E ratio is 5.99. In terms of profitability, STLNW's ROE is N/A, compared to GMRS's ROE of +0.16%. Regarding short-term risk, STLNW is less volatile compared to GMRS. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check GMRS's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, EHAB has a market cap of 706.9M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while EHAB trades at $13.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas EHAB's P/E ratio is -197.14. In terms of profitability, STLNW's ROE is N/A, compared to EHAB's ROE of -0.01%. Regarding short-term risk, STLNW is more volatile compared to EHAB. This indicates higher risk in terms of short-term price fluctuations for STLNW.Check EHAB's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, STLN has a market cap of 646.4M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while STLN trades at $6.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas STLN's P/E ratio is N/A. In terms of profitability, STLNW's ROE is N/A, compared to STLN's ROE of +2.10%. Regarding short-term risk, STLNW is less volatile compared to STLN. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check STLN's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, SRTA has a market cap of 539.9M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while SRTA trades at $6.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas SRTA's P/E ratio is -29.41. In terms of profitability, STLNW's ROE is N/A, compared to SRTA's ROE of +0.14%. Regarding short-term risk, STLNW is less volatile compared to SRTA. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check SRTA's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, TOI has a market cap of 512.9M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while TOI trades at $5.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas TOI's P/E ratio is -14.25. In terms of profitability, STLNW's ROE is N/A, compared to TOI's ROE of +2.10%. Regarding short-term risk, STLNW is less volatile compared to TOI. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check TOI's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while MCTA trades at $29.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas MCTA's P/E ratio is 419.36. In terms of profitability, STLNW's ROE is N/A, compared to MCTA's ROE of -2.33%. Regarding short-term risk, STLNW is more volatile compared to MCTA. This indicates higher risk in terms of short-term price fluctuations for STLNW.Check MCTA's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, CYH has a market cap of 426.6M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while CYH trades at $3.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas CYH's P/E ratio is 4.14. In terms of profitability, STLNW's ROE is N/A, compared to CYH's ROE of +0.21%. Regarding short-term risk, STLNW is less volatile compared to CYH. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check CYH's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, AUNA has a market cap of 389.7M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while AUNA trades at $5.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas AUNA's P/E ratio is 4.74. In terms of profitability, STLNW's ROE is N/A, compared to AUNA's ROE of +0.04%. Regarding short-term risk, STLNW is less volatile compared to AUNA. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check AUNA's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, VMD has a market cap of 337.1M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while VMD trades at $8.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas VMD's P/E ratio is 24.58. In terms of profitability, STLNW's ROE is N/A, compared to VMD's ROE of +0.10%. Regarding short-term risk, STLNW is less volatile compared to VMD. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check VMD's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while CSU trades at $33.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas CSU's P/E ratio is 0.67. In terms of profitability, STLNW's ROE is N/A, compared to CSU's ROE of -0.33%. Regarding short-term risk, STLNW is less volatile compared to CSU. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check CSU's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, AIRS has a market cap of 193.3M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while AIRS trades at $2.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas AIRS's P/E ratio is -91.33. In terms of profitability, STLNW's ROE is N/A, compared to AIRS's ROE of -0.13%. Regarding short-term risk, STLNW is less volatile compared to AIRS. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check AIRS's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, JYNT has a market cap of 120.3M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while JYNT trades at $8.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas JYNT's P/E ratio is 84.40. In terms of profitability, STLNW's ROE is N/A, compared to JYNT's ROE of +0.22%. Regarding short-term risk, STLNW is less volatile compared to JYNT. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check JYNT's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while FVE trades at $2.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas FVE's P/E ratio is -5.64. In terms of profitability, STLNW's ROE is N/A, compared to FVE's ROE of -0.15%. Regarding short-term risk, STLNW is less volatile compared to FVE. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check FVE's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while KDLYW trades at $18.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas KDLYW's P/E ratio is N/A. In terms of profitability, STLNW's ROE is N/A, compared to KDLYW's ROE of -1.05%. Regarding short-term risk, STLNW is less volatile compared to KDLYW. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check KDLYW's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, PARK has a market cap of 93.1M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while PARK trades at $20.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas PARK's P/E ratio is 27.85. In terms of profitability, STLNW's ROE is N/A, compared to PARK's ROE of -0.18%. Regarding short-term risk, STLNW is less volatile compared to PARK. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check PARK's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, BTMD has a market cap of 71M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while BTMD trades at $1.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas BTMD's P/E ratio is 14.64. In terms of profitability, STLNW's ROE is N/A, compared to BTMD's ROE of -0.09%. Regarding short-term risk, STLNW is less volatile compared to BTMD. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check BTMD's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while ALR trades at $1.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas ALR's P/E ratio is -1.11. In terms of profitability, STLNW's ROE is N/A, compared to ALR's ROE of -0.15%. Regarding short-term risk, STLNW is less volatile compared to ALR. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check ALR's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, DCGO has a market cap of 42.9M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while DCGO trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas DCGO's P/E ratio is -0.23. In terms of profitability, STLNW's ROE is N/A, compared to DCGO's ROE of -1.16%. Regarding short-term risk, STLNW is less volatile compared to DCGO. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check DCGO's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, CCEL has a market cap of 33.9M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while CCEL trades at $4.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas CCEL's P/E ratio is -14.00. In terms of profitability, STLNW's ROE is N/A, compared to CCEL's ROE of +0.14%. Regarding short-term risk, STLNW is less volatile compared to CCEL. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check CCEL's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, PIII has a market cap of 33.8M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while PIII trades at $10.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas PIII's P/E ratio is -0.31. In terms of profitability, STLNW's ROE is N/A, compared to PIII's ROE of +1.61%. Regarding short-term risk, STLNW is less volatile compared to PIII. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check PIII's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while IMAC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas IMAC's P/E ratio is -2.27. In terms of profitability, STLNW's ROE is N/A, compared to IMAC's ROE of +0.00%. Regarding short-term risk, STLNW is less volatile compared to IMAC. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check IMAC's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, PIIIW has a market cap of 28.8M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while PIIIW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas PIIIW's P/E ratio is N/A. In terms of profitability, STLNW's ROE is N/A, compared to PIIIW's ROE of +1.61%. Regarding short-term risk, STLNW is less volatile compared to PIIIW. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check PIIIW's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, EUDA has a market cap of 25.4M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while EUDA trades at $13.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas EUDA's P/E ratio is -25.66. In terms of profitability, STLNW's ROE is N/A, compared to EUDA's ROE of +1.20%. Regarding short-term risk, STLNW is less volatile compared to EUDA. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check EUDA's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while CANO-WT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, STLNW's ROE is N/A, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, STLNW is less volatile compared to CANO-WT. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check CANO-WT's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while AIH trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas AIH's P/E ratio is -2.78. In terms of profitability, STLNW's ROE is N/A, compared to AIH's ROE of +1.16%. Regarding short-term risk, STLNW is less volatile compared to AIH. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check AIH's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while CANO trades at $2.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas CANO's P/E ratio is -0.01. In terms of profitability, STLNW's ROE is N/A, compared to CANO's ROE of -1.49%. Regarding short-term risk, STLNW is less volatile compared to CANO. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check CANO's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, FPCG has a market cap of 10.1M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while FPCG trades at $1,025.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas FPCG's P/E ratio is 0.09. In terms of profitability, STLNW's ROE is N/A, compared to FPCG's ROE of +0.00%. Regarding short-term risk, STLNW is more volatile compared to FPCG. This indicates higher risk in terms of short-term price fluctuations for STLNW.Check FPCG's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, AMS has a market cap of 9.9M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while AMS trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas AMS's P/E ratio is -5.92. In terms of profitability, STLNW's ROE is N/A, compared to AMS's ROE of -0.07%. Regarding short-term risk, STLNW is less volatile compared to AMS. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check AMS's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while FTRP trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas FTRP's P/E ratio is -1.22. In terms of profitability, STLNW's ROE is N/A, compared to FTRP's ROE of -0.62%. Regarding short-term risk, STLNW is less volatile compared to FTRP. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check FTRP's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, BMGL has a market cap of 7.8M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while BMGL trades at $5.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas BMGL's P/E ratio is -0.94. In terms of profitability, STLNW's ROE is N/A, compared to BMGL's ROE of -1.74%. Regarding short-term risk, STLNW is less volatile compared to BMGL. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check BMGL's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, AIDX has a market cap of 6.7M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while AIDX trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas AIDX's P/E ratio is -1.03. In terms of profitability, STLNW's ROE is N/A, compared to AIDX's ROE of +1.76%. Regarding short-term risk, STLNW is less volatile compared to AIDX. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check AIDX's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while MODV trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas MODV's P/E ratio is -0.06. In terms of profitability, STLNW's ROE is N/A, compared to MODV's ROE of +1.36%. Regarding short-term risk, STLNW is more volatile compared to MODV. This indicates higher risk in terms of short-term price fluctuations for STLNW.Check MODV's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while GBNH trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas GBNH's P/E ratio is -0.06. In terms of profitability, STLNW's ROE is N/A, compared to GBNH's ROE of +15.74%. Regarding short-term risk, STLNW is less volatile compared to GBNH. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check GBNH's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while RHE-PA trades at $0.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, STLNW's ROE is N/A, compared to RHE-PA's ROE of +1.09%. Regarding short-term risk, STLNW is less volatile compared to RHE-PA. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check RHE-PA's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while RHE trades at $2.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas RHE's P/E ratio is -1.79. In terms of profitability, STLNW's ROE is N/A, compared to RHE's ROE of -1.31%. Regarding short-term risk, STLNW is less volatile compared to RHE. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check RHE's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, TOIIW has a market cap of 4.7M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while TOIIW trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas TOIIW's P/E ratio is -0.17. In terms of profitability, STLNW's ROE is N/A, compared to TOIIW's ROE of +2.10%. Regarding short-term risk, STLNW is more volatile compared to TOIIW. This indicates higher risk in terms of short-term price fluctuations for STLNW.Check TOIIW's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while IMACW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas IMACW's P/E ratio is N/A. In terms of profitability, STLNW's ROE is N/A, compared to IMACW's ROE of +0.73%. Regarding short-term risk, STLNW is less volatile compared to IMACW. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check IMACW's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, EUDAW has a market cap of 1.1M. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while EUDAW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas EUDAW's P/E ratio is 0.04. In terms of profitability, STLNW's ROE is N/A, compared to EUDAW's ROE of +1.20%. Regarding short-term risk, STLNW is less volatile compared to EUDAW. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check EUDAW's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, CCM has a market cap of 741.2K. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while CCM trades at $5.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas CCM's P/E ratio is -0.34. In terms of profitability, STLNW's ROE is N/A, compared to CCM's ROE of +0.06%. Regarding short-term risk, STLNW is less volatile compared to CCM. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check CCM's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, NIVF has a market cap of 110.2K. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while NIVF trades at $0.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas NIVF's P/E ratio is 0.29. In terms of profitability, STLNW's ROE is N/A, compared to NIVF's ROE of +0.33%. Regarding short-term risk, STLNW is less volatile compared to NIVF. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check NIVF's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, MNDR has a market cap of 41.1K. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while MNDR trades at $1.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas MNDR's P/E ratio is -0.04. In terms of profitability, STLNW's ROE is N/A, compared to MNDR's ROE of -0.46%. Regarding short-term risk, STLNW is less volatile compared to MNDR. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check MNDR's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, NIVFW has a market cap of 39.8K. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while NIVFW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas NIVFW's P/E ratio is -0.01. In terms of profitability, STLNW's ROE is N/A, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, STLNW is more volatile compared to NIVFW. This indicates higher risk in terms of short-term price fluctuations for STLNW.Check NIVFW's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, TALKW has a market cap of 33.5K. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while TALKW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas TALKW's P/E ratio is 0.00. In terms of profitability, STLNW's ROE is N/A, compared to TALKW's ROE of +0.00%. Regarding short-term risk, STLNW is less volatile compared to TALKW. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check TALKW's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, KND has a market cap of 0. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while KND trades at $9.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas KND's P/E ratio is -1.14. In terms of profitability, STLNW's ROE is N/A, compared to KND's ROE of -0.53%. Regarding short-term risk, STLNW is less volatile compared to KND. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check KND's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while SLHGP trades at $12.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, STLNW's ROE is N/A, compared to SLHGP's ROE of -0.48%. Regarding short-term risk, STLNW is more volatile compared to SLHGP. This indicates higher risk in terms of short-term price fluctuations for STLNW.Check SLHGP's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, HNGR has a market cap of 0. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while HNGR trades at $18.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas HNGR's P/E ratio is 19.71. In terms of profitability, STLNW's ROE is N/A, compared to HNGR's ROE of +0.52%. Regarding short-term risk, STLNW is more volatile compared to HNGR. This indicates higher risk in terms of short-term price fluctuations for STLNW.Check HNGR's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, DVCR has a market cap of 0. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while DVCR trades at $10.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas DVCR's P/E ratio is 28.34. In terms of profitability, STLNW's ROE is N/A, compared to DVCR's ROE of -0.15%. Regarding short-term risk, STLNW is less volatile compared to DVCR. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check DVCR's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while ATIP-WT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, STLNW's ROE is N/A, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, STLNW is less volatile compared to ATIP-WT. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check ATIP-WT's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, SLHG has a market cap of 0. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while SLHG trades at $0.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas SLHG's P/E ratio is -1.48. In terms of profitability, STLNW's ROE is N/A, compared to SLHG's ROE of N/A. Regarding short-term risk, STLNW is less volatile compared to SLHG. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check SLHG's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, TVTY has a market cap of 0. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while TVTY trades at $32.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas TVTY's P/E ratio is 19.06. In terms of profitability, STLNW's ROE is N/A, compared to TVTY's ROE of +1.75%. Regarding short-term risk, STLNW is more volatile compared to TVTY. This indicates higher risk in terms of short-term price fluctuations for STLNW.Check TVTY's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while TLMDW trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas TLMDW's P/E ratio is N/A. In terms of profitability, STLNW's ROE is N/A, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, STLNW is less volatile compared to TLMDW. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check TLMDW's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, AFAM has a market cap of 0. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while AFAM trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas AFAM's P/E ratio is N/A. In terms of profitability, STLNW's ROE is N/A, compared to AFAM's ROE of +0.06%. Regarding short-term risk, STLNW is less volatile compared to AFAM. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check AFAM's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while DCGOW trades at $1.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas DCGOW's P/E ratio is N/A. In terms of profitability, STLNW's ROE is N/A, compared to DCGOW's ROE of -1.16%. Regarding short-term risk, STLNW is less volatile compared to DCGOW. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check DCGOW's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, TLMD has a market cap of 0. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while TLMD trades at $3.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas TLMD's P/E ratio is -1.60. In terms of profitability, STLNW's ROE is N/A, compared to TLMD's ROE of -0.46%. Regarding short-term risk, STLNW is less volatile compared to TLMD. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check TLMD's competition here

Starling Oncology Inc. Wt (NASDAQ: STLNW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, STLNW stands at 5.5M. In comparison, NFH has a market cap of 0. Regarding current trading prices, STLNW is priced at $0.06 on the NASDAQ, while NFH trades at $11.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

STLNW currently has a P/E ratio of N/A, whereas NFH's P/E ratio is -19.75. In terms of profitability, STLNW's ROE is N/A, compared to NFH's ROE of -0.06%. Regarding short-term risk, STLNW is less volatile compared to NFH. This indicates lower risk in terms of short-term price fluctuations for STLNW.Check NFH's competition here